Microdosing GLP-1. Menopause and weight stability.
Microdosing semaglutide and tirzepatide — sub-therapeutic dosing for menopausal weight stability, what the evidence supports, candidacy.
Prescribing semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) at the low rungs of the dose ladder and deliberately staying there — aiming at appetite stabilization rather than maximal weight loss. The approach draws particular interest for weight stability through menopause. Evidence at sub-standard doses is still emerging; this is physician-judgment territory, and we treat it that way.
Why the scale moves when nothing else changed.
The pattern arrives in our consultations constantly: a woman in her late forties or fifties eating the way she always has, moving the way she always has, and gaining weight anyway — most of it at the midsection. That isn't a discipline failure. It's physiology changing underneath a stable routine.
Estrogen decline redirects fat storage toward the abdomen and the visceral compartment, the metabolically active fat around the organs. At the same time, lean muscle declines faster than before, which lowers resting energy expenditure — the same day's eating now sits atop a smaller metabolic budget. Sleep disruption and shifting insulin sensitivity compound both.
Standard advice — eat less, move more — isn't wrong, but it's incomplete when the baseline itself has moved. This is the context in which sub-standard-protocol GLP-1 dosing, usually called microdosing, has drawn attention: not as a weight-loss program in miniature, but as a way to steady appetite against a physiology that's drifting.
Staying low on the ladder, on purpose.
Microdosing isn't a different product. It's the same semaglutide or tirzepatide, prescribed at the early titration steps — semaglutide held around 0.25 to 0.5 mg weekly, tirzepatide at 2.5 mg — and kept there, rather than climbed every four weeks toward the label maximum.
The goal shifts accordingly. Full protocols pursue the 15-to-21 percent average reductions seen in trials; a microdosed program pursues quieter appetite, steadier weight, and modest reduction where it comes. For a patient whose problem is two to five pounds a year of menopausal drift rather than significant obesity, that reframing is the point.
This is off-label, individualized prescribing — the dose, the molecule, and the exit criteria are set patient by patient. Side effects at low doses are typically milder, since the class's GI effects are dose-dependent, but milder isn't none, and the screening doesn't shrink with the dose.
The registration trials for semaglutide and tirzepatide were run at full therapeutic doses. Controlled trial data on sub-therapeutic dosing for weight stability is limited — what exists is mechanistic reasoning, early reports, and accumulating clinical experience. That's enough to justify a supervised, individualized trial in the right patient; it is not enough to promise outcomes. We say this plainly because the microdosing conversation online often doesn't.
Screened like the full program, because it is one.
A lower dose doesn't lower the bar. Intake is the same as our full weight-loss program: medical history, current medications, baseline labs, and the same contraindication screen — no prescribing with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of pancreatitis, or during pregnancy or attempts to conceive.
Follow-up is the same, too: scheduled visits with weight and symptom review, labs re-checked at clinically appropriate intervals, and a direct line to the clinical team between visits. The cadence may relax sooner than on a full titration, but the structure stays.
We also define the exit before the entry. If appetite and weight haven't stabilized after a reasonable trial, the honest conversation is whether to titrate toward the standard protocol, change molecules, or stop — not to drift on a low dose indefinitely because it's tolerable.
Where hormone replacement therapy fits.
Menopausal weight change is rarely a single-lever problem, and a microdosed GLP-1 only works the appetite lever. Our hormone replacement therapy program addresses the other side — the estrogen decline driving the fat-distribution and body-composition shifts in the first place, along with the sleep and vasomotor symptoms that make weight stability harder.
Plenty of patients run one without the other; some benefit from both, managed by the same physician with one set of labs. We evaluate the two questions together at consultation rather than treating them as separate storefronts.
Supervised by Dr. Charles Peterson, board-certified physician with nearly a decade in aesthetic medicine.
Questions we get.
Does microdosing GLP-1 actually work?
For its stated goal — appetite stabilization and weight maintenance — many patients find low-dose therapy sufficient, and the appetite effect at starting doses is real. For substantial weight loss, full protocols have the evidence. Controlled data at sub-therapeutic doses is limited, so we frame it as a supervised trial with defined goals.
Who is microdosing for?
Most often: menopausal women contending with weight drift rather than significant obesity, patients holding a result after a full program, and patients who tolerate standard titration poorly. It isn't the right tool for patients with substantial weight-loss goals — the full protocol fits that job better.
Is microdosing safer than full-dose therapy?
Gentler, typically — GI side effects are dose-dependent, so low doses usually mean less nausea and constipation. But the contraindications, the screening, and the rare risks of the class don't scale down with the dose. A lower dose is still the medication, prescribed with the same care.
What does a microdosed program cost?
Low-dose programs use less medication, so they sit toward the bottom of the Los Angeles market ranges — semaglutide programs broadly run $300 to $1,000 per month, with starter-dose phases at the low end. Our program pricing is discussed at consultation and shared in writing before starting.
Continue.
GLP-1 mechanism, on-label vs off-label use, candidacy, side-effect management, what happens when you stop.
What is GLP-1? The gut hormone explained — how receptor agonists like semaglutide and tirzepatide mimic it, and why that changes appetite.
Dosing schedule, week-by-week expectations, side-effect timeline, food strategies during titration, the Wegovy vs Ozempic distinction.
Hormone replacement therapy near Calabasas — perimenopause, menopause and andropause care with comprehensive labs and physician oversight.